关于NOVARX公司的肺癌的治疗性疫苗Lucanix (belagenpumatucel-L),该公司总部在SAN DIEGO,我与他们沟通过, 顺便说一下3期临床的情况:
Enrollment in the Phase III clinical trial was completed in June of this year,we will be initiating an interim analysis in the next few months and hope to have results late in January 2013. The final analysis will be in December of 2013 or very early in January 2014. 未来几个月开始分析三期临床实验数据,最迟2013年一月份有报告;该疫苗最后的结果将于2013年底或2014年初公诸于众。
We are very excited about the results to date, and believe that this therapy will offer cancer patients an effective and less toxic alternative to treatment. 我们对目前的实验结果非常满意,希望不久将来可以带给患者有效而又最小副作用的治疗。
该疫苗研究已经进行快10年了,真是不容易,大家坚持住,等到曙光的到来!
|